Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205927 | 0.90 | LOXL2 (0.34) | ADRA2CF2F10LOXL2KMT2A | |
| SCHEMBL5208096 | 0.89 | KMT2A (0.36) | KMT2AGAA | |
| Trifluoroacetic Acid SCHEMBL5209569 | 0.85 | F2 (0.31) | F2 | |
| SCHEMBL6998943 | 0.84 | OPRM1 (0.33) | ADRA2CLOXL2KMT2AL3MBTL1CFD | |
| SCHEMBL5210877 | 0.80 | ADRA2C (0.52) | ADRA2CF2LOXL2ACHEKMT2A | |
| Trifluoroacetic Acid SCHEMBL5209705 | 0.78 | F2 (0.33) | ADRA2CF2F10ACHE | |
| SCHEMBL5204891 | 0.78 | KMT2A (0.33) | ADRA2CF2F10KMT2A | |
| Trifluoroacetic Acid SCHEMBL5206988 | 0.77 | FOLH1 (0.35) | ADRA2CF2F10ACHEOPRM1 | |
| Trifluoroacetic Acid SCHEMBL5629214 | 0.76 | F2 (0.32) | ADRA2CF2F10ACHE | |
| SCHEMBL5208588 | 0.76 | F2 (0.34) | ADRA2CF2F10LOXL2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| EP-1240154-A1 | SERINE PROTEASE INHIBITORS | Tularik Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044226-A1 | SERINE PROTEASE INHIBITORS | TULARIK LIMITED (GB) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | ADRA2C 2090/4885F2 69/4885F10 116/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | ADRA2C 2451/4885F2 122/4885F10 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.